Acute hepatic failure in pediatric H1N1 infection: a case report from Al-Adan Hospital, Kuwait

Fawaz Al-Refaee
Gastroenterology, Hepatology, and Nutrition Unit, Department of Pediatrics, Al-Adan Hospital, Kuwait City, Kuwait

Abstract: Liver involvement in pediatric influenza A (H1N1) infection is rare. Focused clinical evaluation and laboratory tests can rule out or identify hepatic complications early on. Here we report on a 9-year-old boy treated by the Gastroenterology, Hepatology, and Nutrition Unit of Al-Adan Hospital’s Pediatric Department. The patient, who was infected with H1N1 during the 2010 pandemic, showed symptoms of associated acute hepatic failure, was managed conservatively, and recovered completely following treatment. The author would like to draw the attention of pediatricians to the hepatic aspect of human H1N1 infection in order for them to recognize it early and treat it in a timely manner.

Keywords: influenza A (H1N1), infection, acute liver failure, children

Introduction
The 2010 human influenza A (H1N1) virus pandemic seriously affected many countries, including Kuwait. In children, respiratory involvement usually occurs with H1N1; extra pulmonary problems are not common. Liver involvement is rare and needs early identification and treatment. A lack of early intervention can lead to worse outcomes.

Case report
A 9-year-old child was admitted with intermittent low-grade fever, cough, vomiting, and abdominal pain lasting for one week. He received oral antibiotics; the fever subsided initially but reappeared after a few days, along with jaundice. There was no history of skin rash, drug ingestion, or recent travel. He was previously healthy, with no past history of liver disease. On examination, he was alert and oriented, his temperature was 39°C, he was icteric, appeared toxic, was sweating, had a respiratory rate of 30 breaths/minute, and had congested tonsils; a respiratory system exam showed prolonged expiration with expiratory rhonchi. He also had right upper quadrant abdominal tenderness. There were no signs of meningeal irritation, and the rest of his physical examination was unremarkable.

Investigations revealed a hemoglobin (Hb) count of 14.5 g/dL, a total leukocyte count of $3.37 \times 10^9$, neutrophils 19%, lymphocytes 68%, a platelet count of $255 \times 10^9$. Random blood glucose and renal function were both within normal limits. Urinalysis showed mild urobilinogen and ketones, but a urine culture was sterile after 48 hours of incubation. His total serum bilirubin was 66 mmol/L, direct fraction was 37 mmol/L, alanine amino-transferase was 1763 U/L, aspartate amino-transferase
was 1871 units/L, alkaline phosphatase was 246 units/L, and gamma glutamyl transferase was 107 units/L. Prothrombin time was 30 seconds, international normalized ratio was 2.6, albumin count 40 g/L, serum ammonia count 74 mmol/L, and serum lactate 2.06 mmol/L. The patient had normal serum amylase and lipase levels, a negative cold agglutinin test, a normal ultrasound of the abdomen, and a negative chest X-ray. Nasal and throat swabs for H1N1 were positive by a reverse transcription polymerase chain reaction (PCR) test. A hepatitis A, B, and C serological screen was negative, and his serum acetaminophen level was normal. He was treated according to Centers for Disease Control and Prevention (CDC) guidelines with TAMIFLU® (oseltamivir; Genentech, San Francisco, CA) for five days and other supportive measures, including fresh frozen plasma, IV-administered vitamin K, lactulose, and prophylactic intravenous antibiotics. Hepatic parameters were monitored closely. He improved through this treatment and recovered clinically within seven days of admission. His liver enzymes were normalized after two months without any sequel.

### Discussion

Influenza is an acute and generally self-limited respiratory illness. Severe infection is characterized by pneumonia, sepsis, septic shock, and multi-organ failure. Extra-pulmonary involvement is rare in uncomplicated human infections. Studies of mouse models suggest multiple organ localization, including the lungs, heart, thymus, liver, and spleen. Sánchez-Torrent et al reported H1N1 encephalitis in a 3-month-old infant from Spain. Hepatic involvement is not frequent and accounts for less than 3% of all cases. El-Shabrawi et al, in 2011, reported a 10-month-old child with acute myocarditis and fulminant hepatic failure associated with H1N1. The subject of the current case report had acute hepatic failure that presented as jaundice, elevated liver enzymes, and coagulopathy. Most of the other causes of liver failure had been ruled out by relevant investigations. He responded well to antiviral and other supportive treatment, and showed full clinical and laboratory recovery.

Liver affection in influenza virus infections has been shown in experimental animal models. No viral replication is needed to produce hepatic damage, as there is evidence of hepatic oxidative stress and a decrease in antioxidant defenses even when the virus is isolated only from the lungs. This might be explained by the production of pro-inflammatory cytokines in the respiratory airway that leads to changes in hepatic metabolism and enzymatic activities.

### Conclusion

Even though hepatic complications are rare in pediatric H1N1 cases, in reporting this case we would like to draw the attention of pediatric health care professionals to the importance of early recognition, focused investigations, diagnosis, and treatment of complicated human H1N1 infection.

### Disclosure

The author reports no conflicts of interest in this work.

### References

1. Carrillo-Esper R, Pérez-Bustos E, Ornelas-Arroyo S, Albores-Saavedra J, Uribe M. Liver involvement in severe human influenza A H1N1. Ann Hepatol. 2010;9(1):107–111.
2. Abdel-Haq NM, Asmar BI Novel swine—origin influenza A: the 2009 H1N1 influenza virus. Indian J of Pediatr. 2011;78:74–80.
3. CDC H1N1 Flu [webpage on the Internet]. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Atlanta, GA: Centers for Disease Control and Prevention (CDC); 2009. Available from: http://www.cdc.gov/h1n1flu/recommendations.htm. Accessed 7 December, 2009.

4. Fislová T, Gocník M, Sládková T, et al. Multiorgan distribution of human influenza A virus strains observed in a mouse model. Arch Virol. 2009;154(3):409–419.

5. Sánchez-Torrent L, Triviño-Rodriguez M, Suero-Toledano P, et al. Novel influenza A (H1N1) encephalitis in a 3-month-old infant. Infection. 2010;38(3):227–229.

6. El-Shabrawi MHF, Bazaraa HM, Zekri H, Rady HI. Fatal acute myocarditis and fulminant hepatic failure in an infant with pandemic human influenza A, H1N1 (2009) virus infection. J Adv Research. 2011;2(2):191–194.

7. Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl. 2000;6(5):531–542.

8. Murphy MG, Crocker JF, Lee SH, Acott P, Her H. Sequestration of coenzyme A by the industrial surfactant, Toximul MP8. A possible role in the inhibition of fatty acid beta-oxidation in surfactant/influenza B virus mouse model for acute hepatic encephalopathy. Biochim Biophys Acta. 1997;1361(1):103–113.